Results 171 to 180 of about 29,954 (264)

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

open access: yesMolecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi   +11 more
wiley   +1 more source

[Diagnosis and management of diabetes and co-existing osteoporosis (Update 2026)]. [PDF]

open access: yesWien Klin Wochenschr
Muschitz C   +4 more
europepmc   +1 more source

Isoginkgetin protects against degeneration of ALS motor neurons via regulating the GSK-3β-TFEB signaling axis.

open access: yesPharmacol Res
Li A   +13 more
europepmc   +1 more source

Astrocyte heterogeneity in brain metastases

open access: yesMolecular Oncology, EarlyView.
Astrocytes emerge as pivotal regulators of metastatic colonization, survival, immune remodeling, and therapy response associated with an increasing heterogeneity that requires spatially and longitudinally resolved approaches to uncover regulatory programs and guide context‐specific therapies.
Carolina Hernández‐Oliver   +2 more
wiley   +1 more source

From Dish to Trial: Building Translational Models of ALS. [PDF]

open access: yesCells
Salamotas I   +6 more
europepmc   +1 more source

Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB): A Translational Pharmacodynamic Biomarker for PIKfyve Inhibition With VRG50635. [PDF]

open access: yesClin Transl Sci
Gontier G   +18 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy